DEVELOPMENT OF A GUIDANCE FOR INCLUDING PATIENT-REPORTED OUTCOMES (PROS) IN POST-APPROVAL CLINICAL TRIALS OF ONCOLOGY DRUGS FOR COMPARATIVE EFFECTIVENESS RESEARCH (CER)
被引:13
作者:
Basch, E. M.
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USAMem Sloan Kettering Canc Ctr, New York, NY 10021 USA
Basch, E. M.
[1
]
论文数: 引用数:
h-index:
机构:
Abernethy, A.
[2
]
Mullins, C. D.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Maryland, Sch Pharm, Baltimore, MD 21201 USAMem Sloan Kettering Canc Ctr, New York, NY 10021 USA
Mullins, C. D.
[3
]
Tiglao, M. R.
论文数: 0引用数: 0
h-index: 0
机构:
Ctr Med Technol & Policy, Baltimore, MD USAMem Sloan Kettering Canc Ctr, New York, NY 10021 USA
Tiglao, M. R.
[4
]
Tunis, S. R.
论文数: 0引用数: 0
h-index: 0
机构:
Ctr Med Technol & Policy, Baltimore, MD USAMem Sloan Kettering Canc Ctr, New York, NY 10021 USA
Tunis, S. R.
[4
]
机构:
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA